Deerfield Management’s CytomX Therapeutics CTMX Stock Holding History

Deerfield Management’s Portfolio CTMX Stock Details CTMX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-622,548	Closed	-$9.4M	–	96
2018 Q4	$9.4M	Sell	622,548 -107,400	-15%	-$1.59M	0.38%	61
2018 Q3	$13.5M	Hold	729,948	–	–	0.48%	63
2018 Q2	$16.7M	Sell	729,948 -23,374	-3%	-$597K	0.59%	65
2018 Q1	$21.4M	Hold	753,322	–	–	0.74%	54
2017 Q4	$15.9M	Sell	753,322 -3,500	-0.5%	-$72.6K	0.63%	51
2017 Q3	$13.8M	Hold	756,822	–	–	0.62%	53
2017 Q2	$11.7M	Sell	756,822 -186,611	-20%	-$2.81M	0.63%	46
2017 Q1	$16.3M	Hold	943,433	–	–	0.63%	52
2016 Q4	$10.4M	Hold	943,433	–	–	0.43%	59
2016 Q3	$14.8M	Hold	943,433	–	–	0.69%	42
2016 Q2	$9.64M	Hold	943,433	–	–	0.38%	57
2016 Q1	$12.2M	Sell	943,433 -2,589	-0.3%	-$36K	0.52%	54
2015 Q4	$19.7M	Buy	+946,022	New	+$15M	0.8%	42

Other funds holding CTMX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Deerfield Management's CTMX Position: Q1 2019 in Review

Deerfield Management sold out of CytomX Therapeutics (CTMX) in Q1 2019, closing a stake of 622,548 shares — an estimated $9.4M sold.

Deerfield Management first reported a position in CTMX in Q4 2015 and held it in 13 quarters. The position peaked at $21.4M in Q1 2018. 113 funds tracked by Wall St. Rank hold CTMX as of Q1 2019.

Deerfield Management reported no remaining CytomX Therapeutics position as of Q1 2019 after selling out during the quarter.
Deerfield Management sold 622,548 CytomX Therapeutics shares in Q1 2019, an estimated $9.4M.
Deerfield Management first reported a position in CytomX Therapeutics in Q4 2015 and held it in 13 quarters.
Deerfield Management's CytomX Therapeutics position peaked at $21.4M in Q1 2018.
113 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q1 2019.

Based on Deerfield Management's 13F filing for Q1 2019, filed 15 May 2019.